We recently found evidence indicating that the source of elevated serum insulin-like growth factor binding protein (IGFBP)-2 in leukemia was the leukemic T-cells. Here we report that locally produced IGF-II affects IGFBP-2 expression and growth of leukemic cells through the IGF type I receptor. We measured IGFBP-2, -4 and IGF type I receptor (IGF-I-R) mRNA by RT-PCR, cell growth and IGFBP-2 secretion (per 10 6 cells). IGF-I-R binding sites were assessed by 125 I-IGF replacement studies. Inhibition using an IGF-II antibody showed that tumor cell-derived IGF-II accounts for a significant 25% (P<0.001) increase in IGFBP-2 secretion and enhanced growth (P<0.01) of leukemic T-cells after 7 days in culture. IGFBP-2 secretion, but not IGFBP-2 mRNA was specifically increased by IGFs, while no specific effect of insulin was detectable. The addition of 100 ng/ml IGF-II enhanced the IGFBP-2 secretion 2.8-fold, while the use of IGF-I only enhanced IGFBP-2 secretion 1.7-fold, although IGF-I enhanced IGF-II action. Through inhibition using JB1, a peptide inhibiting the IGF signal transduction by blocking the IGF-I-R, we demonstrated the involvement of the IGF-I-R in IGFBP-2 and -4 expression and leukemic cell growth. However, only slight differences in the IGF-I-R mRNA expression were seen for T-and B-cells compared with the differences found for the IGFBP-2 and -4 mRNA or IGFBP-2 secretion. Thus, although IGF-I-R mediates the autocrine/paracrine effects of the IGFs, IGF-I-R mRNA expression is most probably not involved in the differential IGFBP-2/IGFBP-4 expression in leukemic cells.
Introduction
Insulin-like growth factors (IGFs) stimulate cell growth and differentiation (see (1) for review). IGF-I mediates growth hormone action in post-natal life, while IGF-II is highly expressed in fetal tissues. Cellular responses to IGFs are mediated by way of the IGF receptors and are affected by at least seven IGF binding proteins (IGFBP-1 to -6 (2); IGFBP-7 (3)). IGFBPs modulate IGF actions by altering their half-lives and by competing with IGF receptors (1, 4) . IGF receptor expression, cell cycle and other growth factors can affect the tissue-specific production of IGFs and IGFBPs. Analogous to the pattern of expression in fetal tissues, high expression of IGF-II and IGFBP-2 was detectable in many tumors, e.g. leukemia (5) (6) (7) (8) (9) . Furthermore, the growth of some tumors was found to be associated with disorders in IGF-II expression. In rhabdomyosarcoma, for instance, relaxation during imprinting of the maternal allele of the IGF-II gene (10, 11) led to IGF-II overexpression. This, in turn, could stimulate growth and possibly even IGFBP-2 expression in tumor cells. In Wilms' tumor, a point mutation of the WT1 gene, encoding for a transacting factor of IGF receptor type I (IGF-I-R) transcription, caused deregulation of the IGF signal transduction by means of IGF-I-R overexpression (12) . Elevated IGF-I-R expression could also be detected in some lymphoblastic cell lines (13) , although a genetic predisposition has not yet been established in leukemia. Clinical studies (14, 15) have shown that the occasionally high IGFBP-2 levels in leukemic serum normalize after hematological remission following chemotherapy. We recently found evidence that leukemic T-cells could cause elevated IGFBP-2 concentrations in leukemic serum (6) . In an earlier study (16) , IGF-I-R involvement in the growth of leukemic B-and T-cells was presumed. In addition, there is evidence that IGFBP-2 and IGFBP-4, unlike IGFBP-1 and IGFBP-3 (to which mainly endocrine functions are ascribed (1)), modulate the action of IGFs locally. We therefore hypothesized that IGFBP-2 expression in leukemic T-cells is stimulated by IGF-II to modulate the mitogenic action of locally secreted IGF-II. Hence, we investigated the regulation of tumor cell growth and IGFBP-2 and -4 expression in leukemic T-and B-cell lines (6) . Our aim was to establish whether IGF-II exerts an autocrine/paracrine effect and whether the IGF-I-R is involved in this regulation.
Materials and methods

Cell culture and growth factor treatment
Leukemic B-cell (Raji) and T-cell (Molt-4) lines were cultured in serum-free (SFM) RPMI 1640 medium (6) for up to seven days. Cells were counted using a Coulter counter (Cobas Minos STE, Hoffmann LaRoche, Basel, Switzerland). In order to study the effects of growth factors, the leukemic cells were cultured in SFM containing different final concentrations (10, 50 or 100 ng/ml) of IGF-I (a kind gift from Pharmacia and Upjohn, Stockholm, Sweden), IGF-II (Mediagnost, Tü bingen, Germany) and insulin (Sigma, Deisenhofen, Germany). Seventy nanograms per milliliter IGF-II were used as a high physiological concentration for elaboration of the time course of IGFBP-2 secretion. In a subset of experiments, 1.0 mg/ml of the IGF analog JB1 (16) was added to the SFM to block IGF-I-R binding sites. High concentrations (>200 ng/ml) of JB1 could replace IGF-I, thus demonstrating specifity of IGF-I binding for the IGF-I-R binding sites. Since high amounts of IGF-II (6) are known to be secreted by Molt-4 cells, we also added an excess amount (700 ng/ml) of a monoclonal IGF-II antibody (DPC Biermann, Bad Nauheim, Germany) with the aim of suppressing the possible autocrine/paracrine effect of IGF-II.
Reverse transcriptase (RT)-PCR analysis of specific mRNAs
RT-PCR analysis was carried out to study the effects of growth factors on IGFBP-2, -4 and IGF-I-R mRNA expression. First, total RNA was isolated from >10 6 cells. Semi-quantitative PCR was performed using glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression of each sample (set to 100 units), which served as an internal control of mRNA expression as described (6) . Criteria for primer choice were the following: regarding the protein structure of the aligned IGFBP-1 to -6 sequences, we chose primers (with no intra-and intermolecular homologies), referring to the middle domain of the mature IGFBP-2 and -4, i.e. the respective cDNA, where minimum homology is found between IGFBPs (1). As far as possible, the exonic primers span at least one intron to avoid false positive signals due to genomic DNA, although DNAse treatment has been carried out. PCR procedures, i.e. annealing temperature, time and Mg 2þ concentration were optimized for each primer pair. Primer pairs were (a) IGFBP-2 (6), nucleotides 572-741, (b) IGFBP-4 (sense) sn5 0 -ATCGAGGCCAT CCAGGAA-3 0 ; (antisense) asn5 0 -AAA GCTGTCA GCCAGCTG-3 0 , nucleotides 255-705, (c) IGF type I receptor IGF-I-R: sn5 0 -ACAGAGAACCC-CAA GACTGAGG-3 0 ; asn5 0 -TGATGTTGTAGGTGTCTGCGGC-3 0 , nucleotides 7585-7993. After electrophoresis, PCR products were quantified densitometrically (CS1, Cybertech, Berlin, Germany) by using a specific software package (WinCam 2.1, Cybertech).
Specific radioimmunoassay for IGFBP-2
IGFBP-2 secretion by the cells was measured in conditioned medium by specific radioimmunoassay (RIA) as described previously (6) . No difference in IGFBP-2 antibody binding was found between noncomplexed IGFBP-2 and IGFBP-2 complexed with IGF-I or IGF-II. Intra-and interassay variation of the IGFBP-2 RIA (sensitivity: 0.2 ng/ml) was 8.8 and 10.7% respectively. IGFBP-2 secretion is shown for 10 6 cells.
Receptor binding of 125 I-labeled IGF-I on leukemic cells
The After the cells were transferred to small centrifuge tubes and carefully washed (twice) with PBS, the cell pellet-associated radioactivity was measured using a g-counter (Berthold, Wildbad, Germany). Curve-fitting and data analyses were conducted using the PC-LIGAND 3.1 program (developed by P Munson, GraphPad Software Inc., San Diego, CA, USA).
Statistical methods
Data were analyzed using standard statistical methods, including a paired Student's t-test. Results are reported as the mean Ϯ S.E.M. of three or more independent experiments and significance was assigned a value of P<0.05, for differences between values of growth factor-treated cells and controls. Figure 1 shows the influence of treatment with different concentrations of IGF-I, IGF-II and insulin on secretion (Fig. 1a) and mRNA expression of IGFBP-2 (Fig. 1b,  Table 1 ) in the leukemic T-cell line Molt-4. In an earlier report, Molt-4 cell lines -in contrast to leukemic B-cell lines -showed high expression of IGFBP-2 (6). We observed significant stimulation of IGFBP-2 mRNA expression only when using 50 ng/ml IGF-II, and not with any IGF-I or insulin concentration. Higher doses (50 and 100 ng/ml) of IGF-II led to minor, but insignificant, stimulation of IGFBP-2, IGFBP-4 and IGF-I-R mRNA. However, in contrast to insulin, IGF-I and IGF-II led to a marked, dose-dependent specific increase in the secretion of IGFBP-2 in leukemic T-cells. The increase in IGFBP-2 observed in insulin-treated cells was fully compensated by the increased cell number. IGF-II was 2.5 to 2.8 times more effective than IGF-I (P<0.001), and its action could be enhanced by 25% (P<0.01) in combination with IGF-I. Obviously, the IGFs regulate IGFBP-2 secretion in leukemic T-cells post-transcriptionally, rather than at the transcriptional level.
Results
Dose-dependent effects of IGF-I, IGF-II and insulin on IGFBP-2 expression
Autocrine/paracrine IGF-II action on IGFBP-2 synthesis and cell growth Figure 2 shows the time course of secretion of IGFBP-2 ( Fig. 2a) and cell growth (Fig. 2b) in Molt-4 cells under the influence of IGF-II for 7 days. Statistical significances of the differences are given in Table 2 . IGFBP-2 concentrations increased time-dependently in the conditioned medium of cells which were not treated with IGFs (control). A highly significant (Table 2 ) further increase in IGFBP-2 secretion (P<0.001) and cell growth (P<0.01) resulted after addition of 70 ng/ml IGF-II. In contrast, the effect of IGF-I was less pronounced (see also Fig. 1a) . In previous experiments 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) proliferation assay have revealed a stimulating effect of IGFs on the proliferation of lymphocytes (not shown). The use of a monoclonal IGF-II antibody strongly inhibited the action of locally-secreted IGF-II on both IGFBP-2 secretion (P<0.001) and cell growth. The inhibition caused by the IGF antagonist JB1, a peptide which closely binds to IGF-I-R (17), demonstrated the involvement of IGF-I-R in IGFBP-2 regulation and cell growth. After an initial phase (four days) of insignificant inhibition of IGFBP-2, the secretion came to a complete halt, while partial inhibition of cell growth began on the first day. This suggests that IGF-I-R is strongly involved in the mediation of the autocrine/ paracrine action of IGF-II. Table 2 ). 
Expression of IGF type I receptor, IGFBP-2 and IGFBP-4 mRNA
Discussion
The IGFs are known to stimulate the growth of tumor cells (7, 8) . As IGF-II is predominantly a fetal growth factor (1), elevated expression of IGF-II may be a sign for partial re-establishment of an embryonal genetic program in the tumor cells. We had previously shown that leukemic T-, but not B-cell lines secreted IGF-II and expressed high IGFBP-2 mRNA and protein (6) . Since the lymphoblastic IGFBP-2 expression appears to be about an order of magnitude higher than in normal Band T-lymphocytes (6, 18, J L Föll, L Dannecker, C Zehrer, S Hettmer, M W Elmlinger, D Niethammer, M B Ranke & G E Dannecker, unpublished observations), an IGFBP-2 overexpression is likely in leukemic cells. The IGF-II/mannose-6-phosphate receptor in lymphoblastic cells was found to be mainly regulated by developmental factors (19) . Therefore, we focused on the IGF-I-receptor expression. The present study revealed two major findings. First, we demonstrated a specific effect of IGF-II, produced by the tumor cells, as an autocrine/paracrine stimulator of IGFBP-2 production and enhanced growth of leukemic T-cells. Since the concentrations of IGFBP-2 and -4 were adjusted to the cell number, all changes shown can be considered as specific, i.e. independent of cell growth. A significant (P<0.001), strong decrease in IGFBP-2 secretion, and a slight decrease in IGFBP-2 and IGFBP-4 mRNA (P<0.05) were seen after neutralization of locally produced IGF-II by the use of the IGF-II antibody. The inhibition by the IGF-II antibody also revealed an autocrine/paracrine effect of IGF-II on leukemic cell growth. The addition of IGF-I and IGF-II stimulated IGFBP-2 secretion, but IGFBP-2 and IGFBP-4 EUROPEAN JOURNAL OF ENDOCRINOLOGY (1998) 138 Table 2 Statistical significance of differences between cell growth and IGFBP-2 secretion of growth factor-treated (as described in Material and methods) and nontreated leukemic cells after three, five and seven days in culture, corresponding to Fig.  2a JB1 118 Ϯ 11* 322 Ϯ 29*** 451 Ϯ 34*** * P < 0:05, ** P < 0:01, *** P < 0:001 compared with control; n.s., not significant. mRNA accumulation in leukemic T-cells was only poorly stimulated. IGF-I was a weaker stimulator of IGFBP-2 secretion, but could enhance IGF-II action. Even low doses (10 ng/ml) of IGF-I and IGF-II led to a significant (P<0.01) increase in IGFBP-2 secretion. We conclude that post-transcriptional steps rather than cellular mechanisms affecting IGFBP-2 mRNA accumulation regulate IGFBP-2 gene expression. Insulin used in a dose (<100 ng/ml) below that affecting IGF-I-R (20) , was completely ineffective with respect to a specific stimulation of IGFBP-2 synthesis. However, as known from previous studies (21) , insulin enhanced leukemic cell growth (data not shown) by way of the insulin receptor. These results confirm that IGF-II is, as was hypothesized earlier (14) , the most effective known regulator of IGFBP-2 expression.
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The second major finding is that IGF-I-R is present in both the leukemic B-and T-cells, as described earlier (20) and that it is involved in the mediation of the autocrine/paracrine effects of IGF-II. Inhibition of IGF-I-R with JB1, a peptide which blocks the IGF signal transduction (17) , clearly demonstrated that IGF-I-R mediates the autocrine/paracrine actions of IGFs. In particular, cell growth, IGFBP-2 expression, IGFBP-4 mRNA and IGF-I-R mRNA accumulation were affected. However, as IGFBP-2 and -4 mRNA levels were not associated with IGF-I-R mRNA levels, the IGF-I-R mRNA accumulation may not represent the mechanism which triggers the differential expression of IGFBP-2 and -4 and growth of leukemic T-and B-cells. IGF-I-R mRNA levels were also unaffected by exogenous IGF-I or IGF-II. This conflicts with other studies (13, 21) , where altered IGF-I-R expression was found to be associated with tumor growth. However, the IGF-I-R mRNA level was significantly increased by the use of the IGF-II antibody (Table 1) . Clearly, IGF-I-R gene expression (13) is modulated by the autocrine/paracrine action of IGF-II, which is mediated through the IGF-I-R itself. Although the IGF type-II/mannose-6-phosphate receptor had been detected in non-malignant lymphocytes (7, 18, 19) , it was found to be mainly regulated by developmental factors. Hence, the IGF-I-R appears to be a mediator of the IGF actions in leukemic cells.
In an earlier study (9) , it was demonstrated that leukemic cells secrete IGFBP-2 and -4. Here we found evidence that the mRNA expression of both factors is affected in the same way by locally secreted IGF-II via the IGF-I-R. As both IGFBP-2 and -4 are known to modulate the mitogenic action of IGFs (4, 7, J L Föll, L Dannecker, C Zehrer, S Hettmer, M W Elmlinger, D Niethammer, M B Ranke & G E Dannecker, unpublished observations), it is likely that the expression of both factors is increased to modulate the autocrine/ paracrine effects of elevated IGF-II.
